Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy

European Journal of Cancer

Volumn 33, Issue 14, 1997, Pages 2321-2325

  Castiglione Gertsch, M ^a   Tattersall, M ^a   Hacking, A ^a   Goldhirsch, A ^a   Gudgeon, A ^a   Gelber, R D ^a   Lindtner, J ^a   Coates, A ^a   Collins, J ^a   Isley, M ^a   Senn, H J ^a   Rudenstam, C M ^a  

^a International Breast Cancer Study Group Coordinating Center   (Switzerland)

Author keywords

Chemotherapy; Recurrent breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT CANCER; SOFT TISSUE CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031415404     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10011-9     Document Type: Article

References (15)

1. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992, 339, 1-15, 71-85.
2. Goldie JH, Coldman AJ. A mathematical model of relating the drug-sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep. 63:1979;1727-1733.
3. Goldie JH. New information on drug resistance. Implications for the adjuvant treatment of breast cancer. Recent Results Cancer Res. 115:1989;8-16.
4. Goldhirsch A, Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol 1989, 7, 36-44.
5. Valagussa P, Tancini G, Bonadonna G, et al. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 1986, 58, 1411-1417.
6. Falkson G, Gelman R, Glick J, Falkson CI, Harris J. Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 12:1994;45-49.
7. Rubens RD, Bajetta E, Bonneterre J, et al. Treatment of relapse of breast cancer after adjuvant systemic therapy: review and guidelines for future research. Eur J Cancer 1994, 30a, 106-111.
8. Muss HB, Smith LR, Cooper MH. Tamoxifen rechallenge: response to Tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J Clin Oncol. 5:1987;1556-1558.
9. Tattersall MHN. Mechanisms of treatment failure. Recent Results Cancer Res. 127:1993;43-47.
10. Davidson NE, Lippman ME. Stimulation of breast cancer with oestrogens: how much clinical value. Eur J Cancer. 23:1987;897-900.
11. Goldhirsch A, Gelber R, for the Ludwig Breast Cancer Study Group. Adjuvant treatment for early breast cancer: The Ludwig Breast Cancer Studies. NCI Monographs 1986, 1, 55-70.
12. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 1988, 319, 677-683.
13. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989, 320, 491-496.
14. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, et al. for the International Breast Cancer Study Group. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol 1994, 5, 717-724.
15. Goldhirsch A, Gelber RD, Price KN, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994, 343, 377-381.